Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01391273
Other study ID # 192024-059
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date July 1, 2011
Est. completion date May 19, 2012

Study information

Verified date April 2019
Source Allergan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the safety and efficacy of bimatoprost solution 0.03% compared with vehicle in Japanese adults with hypotrichosis of the eyelashes.


Recruitment information / eligibility

Status Completed
Enrollment 173
Est. completion date May 19, 2012
Est. primary completion date May 19, 2012
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Have inadequate eyelashes

Exclusion Criteria:

- Any disease/infection/abnormality of the eye or area around the eye

- Any ocular surgery within 3 months or anticipated need for ocular surgery during the study

- Any permanent eyeliner or implants of any kind or anticipated use of false eyelashes

- Any semi-permanent eyelash tint, dye, curl or eyelash extension application within 3 months

- Use of any over-the-counter eyelash growth product within 6 months or any use of prescription eyelash growth products

- Use of treatments which may affect hair growth (eg, minoxidil, chemotherapy) within 6 months

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
bimatoprost solution 0.03%
One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
bimatoprost vehicle solution
One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Allergan

Country where clinical trial is conducted

Japan, 

References & Publications (1)

Harii K, Arase S, Tsuboi R, Weng E, Daniels S, VanDenburgh A. Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies. Aesthetic Plast Surg. 2014 Apr;38(2):451-60. doi: 10.1007/s00266-014-0293-7. Epub 2014 Mar 19. Erratum in: Aesthetic Plast Surg. 2014 Oct;38(5):1071-2. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA) The investigator evaluated the patient's eyelash prominence using the GEA 4-point scale: 1= minimal, 2= moderate, 3= marked and 4= very marked at Baseline and Month 4. At least a 1-grade increase in the GEA score from Baseline indicated improvement. Baseline, Month 4
Secondary Change From Baseline in Eyelash Length as Measured by Digital Image Analysis (DIA) Photographs were taken of the eyelashes and assessed using DIA. Length was measured in millimeters (mm). Data from both eyes were averaged for each participant for analysis. A positive change from Baseline indicated longer length (improvement). Baseline, Month 4
Secondary Change From Baseline in Eyelash Thickness as Measured by DIA Photographs were taken of the eyelashes and assessed using DIA. Eyelash thickness (fullness) was assessed across both eyes as an average and is measured in millimeters squared (mm^2). A positive change from Baseline indicated fuller eyelashes (improvement). Baseline, Month 4
Secondary Change From Baseline in Eyelash Darkness as Measured by DIA Photographs were taken of the eyelashes and assessed using DIA. Eyelash darkness was measured in both eyes and averaged for analysis using a scale where 0=black and 255=white. A negative change from Baseline indicated darker eyelashes (improvement). Baseline, Month 4
See also
  Status Clinical Trial Phase
Completed NCT01229423 - Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects Phase 4
Completed NCT01623479 - An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes
Completed NCT01064882 - Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence Phase 2
Completed NCT01023841 - Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Phase 4
Completed NCT01391286 - Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis Phase 3
Completed NCT02505776 - Safety and Patient Satisfaction With GLASH VISTAâ„¢ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan